Impact of dose-intensified daunorubicin in induction on patients with core binding factor acute myeloid leukemias

6712 Background: The group of core binding factor (CBF) acute myeloid leukemias (AML) is defined by presence of the t(8;21) or the inv(16) and there is major agreement that high-dose Ara-C (HiDAC) may influence the outcome of those patients. In our institution, we tried two consecutive AML treatment trials including dose-intensified daunorubicin (DNR) in induction comparing to conventional treatments and without HiDAC based consolidation. Purpose: To investigate the impact of dose-intensified DNR in induction on patients with CBF AML, we retrospectively analyzed patients with AML who were treated by DC(T)P(III) or Double-7 therapy which were conducted in our institution from February 1985 and October 2001. Results: Twenty-four of 117 patients (median age, 45 y.o.; range, 17 to 63 y.o.; median PS, 1; range, 0 to 3; male: female, 15: 9) were identified CBF AML and they were assessable for this study. The median dose of DNR in induction was 280 (range, 200 to 400) mg/m2. Four patients underwent autologous PB...